Meet David Steiner

About

David Steiner, PhD, is the executive director of the Johns Hopkins Institute for Education Policy and a professor of education at Johns Hopkins University. He has served in various prominent roles including commissioner of education for New York State, where he played a leading role in the state's successful $700 million Race to the Top application, supporting the redesign of standards, assessments, and teacher certification requirements. His efforts contributed to the launch of EngageNY, a widely consulted free online curriculum resource. Steiner has also served as the Klara and Larry Silverstein Dean at Hunter College School of Education, and as director of education at the National Endowment for the Arts. He holds degrees from Harvard University, including a PhD in political science, and from Balliol College at Oxford University, where he earned both a BA and an MA. Steiner is known for consulting regularly with federal and state education leaders, educational reform organizations, and universities, and has authored numerous articles and books, including his most recent publication, 'A Nation at Thought: Restoring Wisdom in America’s Schools' (2023). His research and professional focus center on education policy, standards, curriculum development, and educational reform.

Research topics

• Internal medicine
• Medicine
• Oncology
• Virology
• Geography
• Pathology
• Urology

Selected publications

• Supplementary Figures and Tables from Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

  2023-03-31

  preprintOpen access

  <p>Supplementary Figures and Tables - PDF file 898K, Supplementary Table ST1: AKR1C3 over-expression in HEK-293 cells reduces IC50 of androgens. Supplementary Table ST2: Finasteride increases the testosterone formation. Supplementary Figure S1: Over-expression of AKR1C3 increases LNCaP xenograft growth in intact mice. Supplementary Figure S2: AR target FKBP51, but not AR, protein expression is increased in LNCaP-AKR1C3 xenograft tumors. Supplementary Figure S3: AKR1C3 translocation to nucl…

  PublisherOA PDFDOI

• Supplementary Methods from Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

  2023-03-31

  preprintOpen access

  <p>Supplementary Methods - PDF file 62K, Additional methods to support the manuscript 1. Cloning and protein purification 2. AKR1C3 enzyme activity and thin layer chromatography (TLC)</p>

  PublisherOA PDFDOI

• Supplementary Figures and Tables from Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

  2023-03-31

  preprintOpen access

  <p>Supplementary Figures and Tables - PDF file 898K, Supplementary Table ST1: AKR1C3 over-expression in HEK-293 cells reduces IC50 of androgens. Supplementary Table ST2: Finasteride increases the testosterone formation. Supplementary Figure S1: Over-expression of AKR1C3 increases LNCaP xenograft growth in intact mice. Supplementary Figure S2: AR target FKBP51, but not AR, protein expression is increased in LNCaP-AKR1C3 xenograft tumors. Supplementary Figure S3: AKR1C3 translocation to nucl…

  PublisherDOI

• Supplementary Methods from Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

  2023-03-31

  preprintOpen access

  <p>Supplementary Methods - PDF file 62K, Additional methods to support the manuscript 1. Cloning and protein purification 2. AKR1C3 enzyme activity and thin layer chromatography (TLC)</p>

  PublisherDOI

• Data from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent

  2023-03-31

  preprintOpen access

  <div>AbstractPurpose:<p>Sabizabulin, an oral cytoskeleton disruptor, was tested in a phase Ib/II clinical study in men with metastatic castration-resistant prostate cancer (mCRPC).</p>Patients and Methods:<p>The phase Ib portion utilized a 3+3 design with escalating daily oral doses of 4.5–81 mg and increasing schedule in 39 patients with mCRPC treated with one or more androgen receptor–targeting agents. Prior taxane chemotherapy was allowed. The phase II portion tested a…

  PublisherDOI

Recent grants

• NIH Grant R01DK047575

  NIH · $483k · 1997

• NIH Grant R01DK054439

  NIH · $1.8M · 2003

Frequent coauthors

• Robert H. Getzenberg

  Nova Southeastern University

  53 shared

• K. Gary Barnette

  46 shared

• Mark C. Markowski

  43 shared

• Mario A. Eisenberger

  43 shared

• Ronald Tutrone

  Chesapeake Urology Associates

  38 shared

• James T. Dalton

  University of Rochester Medical Center

  36 shared

• Emmanuel S. Antonarakis

  University of Minnesota

  35 shared

• Domingo Rodrı́guez

  University of Puerto Rico System

  33 shared

Labs

• Johns Hopkins Institute for Education PolicyPI